ArticleJournal of clinical laboratory analysis2025
Establishment and Application of a Dual Immunoassay Method Based on ICP-MS for Stable Element Labeling Antibodies.
Article in Journal of clinical laboratory analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTo establish a dual immunoassay based on inductively coupled plasma mass spectrometry (ICP-MS) with stable element labeling antibodies for the simultaneous detection of alpha-fetoprotein (AFP) and prostate-specific antigen (PSA) in serum and evaluate its performance and clinical sample validation.
methodsThe immunoassay system based on the double antibody sandwich method was established using magnetic beads as solid-phase carriers and rare earth elements europium (Eu) and samarium (Sm) as element tags. The test conditions were optimized. According to the Clinical Laboratory Standards Institute (CLSI) guidelines and the "Guidelines for Performance Validation of Clinical Chemistry Quantitative Testing Procedures," performance validation was conducted using the established method, followed by clinical sample validation.
resultsThe LOD and AMR for AFP were 0.76 ng/mL and 1.5-1200 ng/mL, respectively; the LOD and AMR for PSA were 0.41 ng/ mL and 0.5-250 ng/ mL, respectively. The intra-batch precision for AFP and PSA was all less than 3.33%, and the inter-batch precision for AFP and PSA was all less than 4.97%. The recoveries of AFP and PSA were 95.08%-104.18% and 97.65%-100.72%, respectively. The correlation coefficients between the established and the CLIA methods were r = 0.9930 for AFP and r = 0.9852 for PSA.
conclusionsWe have developed a dual immunoassay method based on ICP-MS, which can quantitatively detect AFP and PSA in serum within a single analysis. This method exhibits good precision, a wide linear range, and high specificity, meeting the requirements for clinical sample detection and holding potential for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.